By Professor Michelle Haber

Journal articles

Cheung BB; Mittra R; Murray J; Wang Q; Seneviratne JA; Raipuria M; Wong IPL; Restuccia D; Gifford A; Salib A; Sutton S; Huang L; Ferdowsi PV; Tsang J; Sekyere E; Mayoh C; Luo L; Brown DL; Stow JL; Zhu S; Young RJ; Solomon BJ; Chappaz S; Kile B; Kueh A; Herold MJ; Hilton DJ; Liu T; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM, 2024, 'Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis', Communications Biology, 7, pp. 1322, http://dx.doi.org/10.1038/s42003-024-06899-8

Nelson CB; Rogers S; Roychoudhury K; Tan YS; Atkinson CJ; Sobinoff AP; Tomlinson CG; Hsu A; Lu R; Dray E; Haber M; Fletcher JI; Cesare AJ; Hegde RS; Pickett HA, 2024, 'The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-45683-4

Murray JE; Valli E; Milazzo G; Mayoh C; Gifford AJ; Fletcher JI; Xue C; Jayatilleke N; Salehzadeh F; Gamble LD; Rouaen JRC; Carter DR; Forgham H; Sekyere EO; Keating J; Eden G; Allan S; Alfred S; Kusuma FK; Clark A; Webber H; Russell AJ; de Weck A; Kile BT; Santulli M; De Rosa P; Fleuren EDG; Gao W; Wilkinson-White L; Low JKK; Mackay JP; Marshall GM; Hilton DJ; Giorgi FM; Koster J; Perini G; Haber M; Norris MD, 2024, 'The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-49871-0

Seneviratne JA; Ravindrarajah D; Carter DR; Zhai V; Lalwani A; Krishan S; Balachandran A; Ng E; Pandher R; Wong M; Nero TL; Wang S; Norris MD; Haber M; Liu T; Parker MW; Cheung BB; Marshall GM, 2024, 'Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma', Cancer Medicine, 13, pp. e70082, http://dx.doi.org/10.1002/cam4.70082

Salomon R; Li W; Toumari M; Lowe A; Mayoh C; Barahona P; Lau LMS; Staunton J; Jacobson E; Nagabushan S; Manoharan N; Mitchell R; Ong F; Haber M; Ziegler DS; Cowley MJ; Mateos MK, 2024, 'Abstract A044 Enhanced disease detection using single cell RNAseq in children with brain cancer', Cancer Research, 84, pp. A044 - A044, http://dx.doi.org/10.1158/1538-7445.pediatric24-a044

Azzam N; Fletcher JI; Melong N; Lau L; Dolman EM; Mao J; Tax G; Cadiz R; Tuzi L; Kamili A; Dumevska B; Xie J; Chan JA; Senger DL; Grover SA; Malkin D; Haber M; Berman JN, 2024, 'Abstract B007: High-risk pediatric cancer models in zebrafish, mouse and short-term culture predict individual patient responses to therapy', Cancer Research, 84, pp. B007 - B007, http://dx.doi.org/10.1158/1538-7445.pediatric24-b007

Lau LMS; Khuong-Quang D-A; Staunton J; Sanders N; Sriharan S; Trinder S; Manoharan N; Barahona P; Altekoester A-K; Dias K; Rumford M; Sylvester D; Parhar J; Mateos MK; Wong M; Mayoh C; Cowley MJ; Ekert PG; Haber M; Tyrrell V; Ziegler DS, 2024, 'Abstract B012: Clinical utility of real-time comprehensive molecular profiling in childhood brain tumors', Cancer Research, 84, pp. B012 - B012, http://dx.doi.org/10.1158/1538-7445.pediatric24-b012

Mayoh C; Barahona P; Lin A; Cui L; Ajuyah P; Altekoester A; Lau LMS; Khuong-Quang D-A; Tyrrell V; Haber M; Wong-Erasmus M; Ekert PG; Cowley MJ, 2024, 'Abstract B014: Increasing the clinical utility of transcriptome analysis in high-risk childhood precision oncology', Cancer Research, 84, pp. B014 - B014, http://dx.doi.org/10.1158/1538-7445.pediatric24-b014

Hassan N; Yi H; Malik B; Gaspard-Boulinc L; Samaraweera SE; Casolari DA; Seneviratne J; Balachandran A; Chew T; Duly A; Carter DR; Cheung BB; Norris M; Haber M; Kavallaris M; Marshall GM; Zhang XD; Liu T; Wang J; Liebermann DA; D'Andrea RJ; Wang JY, 2024, 'Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML', Blood, 144, pp. 84 - 98, http://dx.doi.org/10.1182/blood.2024024072

Lau LMS; Khuong-Quang DA; Mayoh C; Wong M; Barahona P; Ajuyah P; Senapati A; Nagabushan S; Sherstyuk A; Altekoester AK; Fuentes-Bolanos NA; Yeung V; Sullivan A; Omer N; Diamond Y; Jessop S; Battaglia L; Zhukova N; Cui L; Lin A; Gifford AJ; Fleuren EDG; Dalla-Pozza L; Moore AS; Khaw SL; Eisenstat DD; Gottardo NG; Wood PJ; Tapp H; Alvaro F; McCowage G; Nicholls W; Hansford JR; Manoharan N; Kotecha RS; Mateos MK; Lock RB; Tyrrell V; Haber M; Trahair TN; Cowley MJ; Ekert PG; Marshall GM; Ziegler DS, 2024, 'Precision-guided treatment in high-risk pediatric cancers', Nature Medicine, 30, pp. 1913 - 1922, http://dx.doi.org/10.1038/s41591-024-03044-0

Karsa M; Xiao L; Ronca E; Bongers A; Spurling D; Karsa A; Cantilena S; Mariana A; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Sutton R; Lock RB; Williams O; de Boer J; Haber M; Norris MD; Henderson MJ; Somers K, 2024, 'FDA-approved disulfiram as a novel treatment for aggressive leukemia', Journal of Molecular Medicine, 102, pp. 507 - 519, http://dx.doi.org/10.1007/s00109-023-02414-4

Hogarty MD; Ziegler DS; Franson A; Chi YY; Tsao-Wei D; Liu K; Vemu R; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer B; Balis FM; Groshen S; Norris MD; Haber M; Park JR; Matthay KK; Marachelian A, 2024, 'Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial', British Journal of Cancer, 130, pp. 788 - 797, http://dx.doi.org/10.1038/s41416-023-02525-2

Rouaen JR; Salerno A; Luciani F; Murray J; Shai-Hee T; Tedla N; Haber M; Trahair TN; Vittorio O, 2024, 'Abstract 2673: Copper chelation overcomes the immunosuppressive neuroblastoma microenvironment to potentiate anti-GD2 antibody therapy', Cancer Research, 84, pp. 2673 - 2673, http://dx.doi.org/10.1158/1538-7445.am2024-2673

Hu W; Kumar A; Ahmed SF; Qi S; Ma DKG; Chen H; Singh GJ; Casan JML; Haber M; Voskoboinik I; McKay MR; Trapani JA; Ekert PG; Fareh M, 2024, 'Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing', Nature Structural and Molecular Biology, http://dx.doi.org/10.1038/s41594-024-01336-0

Norris M; Murray J; Valli E; Milazzo G; Mayoh C; Gifford A; Fletcher J; Xue C; Jayatilleke N; Gamble L; De Rosa P; Marshall G; Giorgi F; Koster J; Perini G; Haber M, 2024, '24 (PB012): Runx1t1 is an epigenetic regulator essential for MYCN-driven neuroblastoma tumorigenesis', European Journal of Cancer, 211, pp. 114552 - 114552, http://dx.doi.org/10.1016/j.ejca.2024.114552

Lau L; Khoung-Quang DA; Chelsea M; Wong M; Barahona P; Ajuyah P; Senapati A; Nagabushan S; Sherstyuk A; Altekoester AK; Fuentes-Bolanos N; Sullivan A; Mateos M; Tyrrell N; Haber M; Trahair T; Cowley M; Marshall G; Ekert P; Ziegler D, 2024, '438 (PB426): Precision-guided treatment improves outcomes for children with highrisk cancers', European Journal of Cancer, 211, pp. 114946 - 114946, http://dx.doi.org/10.1016/j.ejca.2024.114946

Mayoh C; Gifford AJ; Terry R; Lau LMS; Wong M; Rao P; Shai-Hee T; Saletta F; Khuong-Quang DA; Qin V; Mateos MK; Meyran D; Miller KE; Yuksel A; Mould EVA; Bowen-James R; Govender D; Senapati A; Zhukova N; Omer N; Dholaria H; Alvaro F; Tapp H; Diamond Y; Pozza LD; Moore AS; Nicholls W; Gottardo NG; McCowage G; Hansford JR; Khaw SL; Wood PJ; Catchpoole D; Cottrell CE; Mardis ER; Marshall GM; Tyrrell V; Haber M; Ziegler DS; Vittorio O; Trapani JA; Cowley MJ; Neeson PJ; Ekert PG, 2023, 'A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer', Genome Medicine, 15, http://dx.doi.org/10.1186/s13073-023-01170-x

Murray J; Pandher R; Xiao L; Somers K; Brand J; Mosmann E; Alfred S; Kusuma F; Kearns A; Park JR; Marshall LV; Gorrini C; Chesler L; Hogarty MD; Pearson ADJ; Burns M; Fletcher JI; Ziegler D; Norris MD; Haber M, 2023, 'Abstract B132: Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone', Molecular Cancer Therapeutics, 22, pp. B132 - B132, http://dx.doi.org/10.1158/1535-7163.targ-23-b132

Ajuyah P; Mayoh C; Lau LMS; Barahona P; Wong M; Chambers H; Valdes-Mora F; Senapati A; Gifford AJ; D’Arcy C; Hansford JR; Manoharan N; Nicholls W; Williams MM; Wood PJ; Cowley MJ; Tyrrell V; Haber M; Ekert PG; Ziegler DS; Khuong-Quang DA; Valdes Mora F, 2023, 'Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes', Scientific Reports, 13, pp. 3775, http://dx.doi.org/10.1038/s41598-023-30395-4

Wakefield CE; Hetherington K; Robertson EG; Donoghoe MW; Hunter JD; Vetsch J; Marron JM; Tucker KM; Marshall GM; Broom A; Haber M; Tyrrell V; Malkin D; Lau L; Mateos MK; O’Brien TA; Ziegler DS, 2023, 'Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives', British Journal of Cancer, 129, pp. 1634 - 1644, http://dx.doi.org/10.1038/s41416-023-02429-1

Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR, 2023, 'Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms242115571

Mayoh C; Mao J; Xie J; Tax G; Chow SO; Cadiz R; Pazaky K; Barahona P; Ajuyah P; Trebilcock P; Malquori A; Gunther K; Avila A; Yun DY; Alfred S; Gopalakrishnan A; Kamili A; Wong M; Cowley MJ; Jessop S; Lau LMS; Trahair TN; Ziegler DS; Fletcher JI; Gifford AJ; Tsoli M; Marshall GM; Haber M; Tyrrell V; Failes TW; Arndt GM; Lock RB; Ekert PG; M Dolman ME; Wong-Erasmus M; Ajuyah P, 2023, 'High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer', Cancer Research, 83, pp. 2716 - 2732, http://dx.doi.org/10.1158/0008-5472.CAN-22-3702

Daly R; Hetherington K; Hazell E; Wadling BR; Tyrrell V; Tucker KM; Marshall GM; Ziegler DS; Lau LMS; Trahair TN; O’Brien TA; Collins K; Gifford AJ; Haber M; Pinese M; Malkin D; Cowley MJ; Karpelowsky J; Drew D; Jacobs C; Wakefield CE, 2023, 'Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial', Journal of Personalized Medicine, 13, http://dx.doi.org/10.3390/jpm13071033

Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M; Moles Meler E, 2023, 'Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia', Science translational medicine, 15, pp. eabm1262 - eabm1262, http://dx.doi.org/10.1126/scitranslmed.abm1262

Hastings JF; Latham SL; Kamili A; Wheatley MS; Han JZR; Wong-Erasmus M; Phimmachanh M; Nobis M; Pantarelli C; Cadell AL; O’Donnell YEI; Leong KH; Lynn S; Geng FS; Cui L; Yan S; Achinger-Kawecka J; Stirzaker C; Norris MD; Haber M; Trahair TN; Speleman F; De Preter K; Cowley MJ; Bogdanovic O; Timpson P; Cox TR; Kolch W; Fletcher JI; Fey D; Croucher DR, 2023, 'Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.abp8314

Ballinger ML; Pattnaik S; Mundra PA; Zaheed M; Rath E; Priestley P; Baber J; Ray-Coquard I; Isambert N; Causeret S; van der Graaf WTA; Puri A; Duffaud F; Le Cesne A; Seddon B; Chandrasekar C; Schiffman JD; Brohl AS; James PA; Kurtz JE; Penel N; Myklebost O; Meza-Zepeda LA; Pickett H; Kansara M; Waddell N; Kondrashova O; Pearson JV; Barbour AP; Li S; Nguyen TL; Fatkin D; Graham RM; Giannoulatou E; Green MJ; Kaplan W; Ravishankar S; Copty J; Powell JE; Cuppen E; van Eijk K; Veldink J; Ahn JH; Kim JE; Lor Randall R; Tucker K; Judson I; Sarin R; Ludwig T; Genin E; Deleuze JF; Haber M; Marshall G; Cairns MJ; Blay JY; Thomas DM, 2023, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', Science, 379, pp. 253 - 260, http://dx.doi.org/10.1126/science.abj4784

Novototskaya-Vlasova KA; Neznanov NS; Molodtsov I; Hall BM; Commane M; Gleiberman AS; Murray J; Haber M; Norris MD; Leonova KI; Gudkov AV, 2022, 'Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors', Proceedings of the National Academy of Sciences of the United States of America, 119, http://dx.doi.org/10.1073/pnas.2213146119

Tang TCY; Xu N; Nordon R; Haber M; Micklethwaite K; Dolnikov A, 2022, 'Donor T cells for CAR T cell therapy', Biomarker Research, 10, pp. 14, http://dx.doi.org/10.1186/s40364-022-00359-3

Hanssen KM; Wheatley MS; Yu DMT; Conseil G; Norris MD; Haber M; Cole SPC; Fletcher JI, 2022, 'GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators', FEBS Journal, 289, pp. 3854 - 3875, http://dx.doi.org/10.1111/febs.16374

Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K, 2022, 'The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression', Frontiers in Oncology, 12, pp. 863329, http://dx.doi.org/10.3389/fonc.2022.863329

Lau LMS; Mayoh C; Xie J; Barahona P; MacKenzie KL; Wong M; Kamili A; Tsoli M; Failes TW; Kumar A; Mould EVA; Gifford A; Chow SO; Pinese M; Fletcher JI; Arndt GM; Khuong-Quang DA; Wadham C; Batey D; Eden G; Trebilcock P; Joshi S; Alfred S; Gopalakrishnan A; Khan A; Grebert Wade D; Strong PA; Manouvrier E; Morgan LT; Span M; Lim JY; Cadiz R; Ung C; Thomas DM; Tucker KM; Warby M; McCowage GB; Dalla-Pozza L; Byrne JA; Saletta F; Fellowes A; Fox SB; Norris MD; Tyrrell V; Trahair TN; Lock RB; Cowley MJ; Ekert PG; Haber M; Ziegler DS; Marshall GM; Trahair T, 2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, 14, pp. emmm202114608, http://dx.doi.org/10.15252/emmm.202114608

Gao J; Jung M; Williams RT; Hui D; Russell AJ; Naim AJ; Kamili A; Clifton M; Bongers A; Mayoh C; Ho G; Scott CL; Jessup W; Haber M; Norris MD; Henderson MJ, 2022, 'Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer', Cancers, 14, pp. 1878, http://dx.doi.org/10.3390/cancers14081878

Karsa M; Ronca E; Bongers A; Mariana A; Moles E; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Kavallaris M; Haber M; Norris MD; Henderson MJ; Xiao L; Somers K; Moles Meler E, 2022, 'Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia', Frontiers in Oncology, 11, pp. 779859, http://dx.doi.org/10.3389/fonc.2021.779859

Seneviratne JA; Carter DR; Mittra R; Gifford A; Kim PY; Luo JS; Mayoh C; Salib A; Rahmanto AS; Murray J; Cheng NC; Nagy Z; Wang Q; Kleynhans A; Tan O; Sutton SK; Xue C; Chung SA; Zhang Y; Sun C; Zhang L; Haber M; Norris MD; Fletcher JI; Liu T; Dilda PJ; Hogg PJ; Cheung BB; Marshall GM, 2022, 'Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma', International Journal of Cancer, 152, pp. 1399 - 1413, http://dx.doi.org/10.1002/ijc.34349

Segura MF; Soriano A; Roma J; Piskareva O; Jiménez C; Boloix A; Fletcher JI; Haber M; Gray JC; Cerdá-Alberich L; Martínez de Las Heras B; Cañete A; Gallego S; Moreno L, 2022, 'Methodological advances in the discovery of novel neuroblastoma therapeutics', Expert Opinion on Drug Discovery, 17, pp. 167 - 179, http://dx.doi.org/10.1080/17460441.2022.2002297

Khan A; Gamble LD; Upton DH; Ung C; Yu DMT; Ehteda A; Pandher R; Mayoh C; Hébert S; Jabado N; Kleinman CL; Burns MR; Norris MD; Haber M; Tsoli M; Ziegler DS, 2021, 'Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas', Nature Communications, 12, pp. 971, http://dx.doi.org/10.1038/s41467-021-20896-z

Fleuren EDG; Terry RL; Meyran D; Omer N; Trapani JA; Haber M; Neeson PJ; Ekert PG, 2021, 'Enhancing the potential of immunotherapy in paediatric sarcomas: Breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors', Biomedicines, 9, pp. 1798, http://dx.doi.org/10.3390/biomedicines9121798

Hanssen KM; Haber M; Fletcher JI, 2021, 'Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition', Drug Resistance Updates, 59, pp. 100795, http://dx.doi.org/10.1016/j.drup.2021.100795

Gifford AJ; Murray J; Fletcher JI; Marshall GM; Norris MD; Haber M, 2021, 'A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma', Current Protocols, 1, pp. e310, http://dx.doi.org/10.1002/cpz1.310

Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB, 2021, 'Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia', Leukemia, 35, pp. 3101 - 3112, http://dx.doi.org/10.1038/s41375-021-01248-8

Meyran D; Terry RL; Zhu JJ; Haber M; Ziegler DS; Ekert PG; Trapani JA; Darcy PK; Neeson PJ, 2021, 'Early-phenotype CAR-T cells for the treatment of pediatric cancers', Annals of Oncology, 32, pp. 1366 - 1380, http://dx.doi.org/10.1016/j.annonc.2021.07.018

Terry RL; Meyran D; Fleuren EDG; Mayoh C; Zhu J; Omer N; Ziegler DS; Haber M; Darcy PK; Trapani JA; Neeson PJ; Ekert PG, 2021, 'Chimeric antigen receptor t cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma', Cancers, 13, pp. 4704, http://dx.doi.org/10.3390/cancers13184704

Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O’Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M, 2021, 'Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma', Clinical Cancer Research, 27, pp. 4338 - 4352, http://dx.doi.org/10.1158/1078-0432.CCR-20-2357

Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K, 2021, 'Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin', British Journal of Cancer, 125, pp. 55 - 64, http://dx.doi.org/10.1038/s41416-021-01332-x

Xiao L; Yeung H; Haber M; Norris MD; Somers K, 2021, 'Immunometabolism: A ‘Hot’ Switch for ‘Cold’ Pediatric Solid Tumors', Trends in Cancer, 7, pp. 751 - 777, http://dx.doi.org/10.1016/j.trecan.2021.05.002

Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS, 2021, 'Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG', Cell Reports, 35, pp. 108994, http://dx.doi.org/10.1016/j.celrep.2021.108994

Gamble LD; Purgato S; Henderson MJ; Di Giacomo S; Russell AJ; Pigini P; Murray J; Valli E; Milazzo G; Giorgi FM; Cowley M; Ashton LJ; Bhalshankar J; Schleiermacher G; Rihani A; Van Maerken T; Vandesompele J; Speleman F; Versteeg R; Koster J; Eggert A; Noguera R; Stallings RL; Tonini GP; Fong K; Vaksman Z; Diskin SJ; Maris JM; London WB; Marshall GM; Ziegler DS; Hogarty MD; Perini G; Norris MD; Haber M, 2021, 'A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma', Cancers, 13, pp. 1807, http://dx.doi.org/10.3390/cancers13081807

Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM, 2021, 'A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma', Oncogene, 40, pp. 2367 - 2381, http://dx.doi.org/10.1038/s41388-021-01712-w

Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY, 2021, 'The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma', Molecular Oncology, 15, pp. 1162 - 1179, http://dx.doi.org/10.1002/1878-0261.12906

Grohmann C; Walker F; Devlin M; Luo MX; Chüeh AC; Doherty J; Vaillant F; Ho GY; Wakefield MJ; Weeden CE; Kamili A; Murray J; Po’uha ST; Weinstock J; Kane SR; Faux MC; Broekhuizen E; Zheng Y; Shield-Artin K; Kershaw NJ; Tan CW; Witchard HM; Ebert G; Charman SA; Street I; Kavallaris M; Haber M; Fletcher JI; Asselin-Labat ML; Scott CL; Visvader JE; Lindeman GJ; Watson KG; Burgess AW; Lessene G, 2021, 'Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors', Cell Death and Disease, 12, pp. 268, http://dx.doi.org/10.1038/s41419-020-03269-0

Back to profile page